Clinical Trial Update: Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating nivolumab with multi-fraction stereotactic radiosurgery, with or without ipilimumab, for recurrent Grade II-III meningioma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Grade 2 Meningioma, Grade 3 Meningioma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING